🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Vassiliki A. Papadimitrakopoulou

Pfizer (United States)

ORCID: 0000-0003-3172-1399
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile
1.9Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973
Top 11%
1.9DataRank
Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Papers

Driven by 16 papers — median percentile 44. Top paper: “Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC”.

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.04.026
N/A
6.8DataRank · unranked
195 citations

Marcelo V. Negrão, Seyedeh Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac +32 more

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

JAMA Oncology(2021)10.1001/jamaoncol.2021.2209
N/A
3.1DataRank · unranked
105 citations

Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.09.013
N/A
2.3DataRank · unranked
79 citations

Mary W. Redman, Susanne M. Arnold, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002973
Top 11%
1.9DataRank
Top 11%47 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002891
N/A
0.854DataRank · unranked
296 citations

Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent K. Shen +33 more

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

The Lancet Oncology(2020)10.1016/s1470-2045(20)30475-7
N/A
0.725DataRank · unranked
125 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +21 more

Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.12.011
N/A
0.678DataRank · unranked
91 citations

Jianjun Zhang, Carol C. Wu, Hai T. Tran, Lerong Li, Lixia Diao +13 more

Spatial PD‐L1, immune‐cell microenvironment, and genomic copy‐number alteration patterns and drivers of invasive‐disease transition in prospective oral precancer cohort

Cancer(2023)10.1002/cncr.34607
N/A
0.406DataRank · unranked
14 citations

Jianjun Zhang, Xin Zhao, Edwin R. Parra, Naohiro Uraoka, Heather Lin +16 more

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad003
N/A
0.330DataRank · unranked
8 citations

Qian Lu, Mary W. Redman, Susan S. Tavernier, Lori M. Minasian, Ellen V. Sigal +17 more

Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9576
N/A
0.165DataRank · unranked
2 citations

Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, David R. Gandara, Fred R. Hirsch, Philip C. Mack +14 more

The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials

Clinical Radiology(2020)10.1016/j.crad.2020.09.024
N/A
0DataRank · unranked
9 citations

Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, J.J. Lee, Joe Ensor, E.S. Kim +9 more

SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9623
Top 100%
0DataRank
Top 100%0 citations

Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +14 more

Deep learning‐based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia

Cancer Medicine(2023)10.1002/cam4.5478
N/A
0DataRank · unranked
40 citations

Frederico O. Gleber‐Netto, Shidan Wang, Roberta Rayra Martins‐Chaves, Ricardo Santiago Gomez, Nadarajah Vigneswaran +15 more

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.10.015
N/A
0DataRank · unranked
11 citations

Mary W. Redman, Karen Kelly, S. Waqar, Francisco Robert, Gauri Kiefer +6 more

Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.08.022
N/A
0DataRank · unranked
98 citations

John V. Heymach, Chunxiao Guo, Hari Menon, Katherine Klein, Taylor R. Cushman +19 more

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.001
N/A
0DataRank · unranked
32 citations

Mary W. Redman, Lauren A. Byers, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz +12 more